US2018071265A1PendingUtilityA1

Method of Treating or Preventing Pathologic Effects of Acute Increases in Hyperglycemia and/or Acute Increases of Free Fatty Acid Flux

57
Assignee: GURTNER GEOFFREY CPriority: May 24, 2004Filed: Jul 28, 2017Published: Mar 15, 2018
Est. expiryMay 24, 2024(expired)· nominal 20-yr term from priority
A61K 31/496A61P 3/10A61K 31/5377A61K 31/4196
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

One aspect of the present invention relates to a method of treating or preventing pathologic effects of hyperglycemia and/or increased fatty acid flux in a subject in need of such treatment or preventive therapy. This method involves administering a composition containing a therapeutically effective amount of a ROS inhibitor to a subject in need thereof.

Claims

exact text as granted — not AI-modified
1 - 19 . (canceled) 
     
     
         20 . A composition of matter comprising the compound R-L-C-M or a pharmaceutically acceptable salt thereof, wherein R is H or a biocompatible moiety capable of facilitating or hindering the penetration of said composition of matter in target cells, L is a linker connecting R to C, wherein L is capable of facilitating a rapid cellular intake and delaying a cellular exit of said composition of matter, C is an iron chelating moiety, and M is a functional-masking group susceptible to cleavage by (OH.). 
     
     
         21 . (canceled) 
     
     
         22 . A therapeutic composition comprising:
 (a) a compound of the formula R-L-C-M or a pharmaceutically acceptable salt thereof; wherein R is H or a biocompatible moiety capable of facilitating or hindering the penetration of said therapeutic composition in target cells, L is a linker connecting R to C, wherein L is capable of facilitating a rapid cellular intake and delaying a cellular exit of said therapeutic composition, C is an iron chelating moiety, and M is a functional-masking group susceptible to cleavage by (OH.), and   (b) a pharmaceutical carrier.   
     
     
         23 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.